Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MONICA VERDUZCO-GUTIERREZ

Allopathic & Osteopathic Physicians Physical Medicine & Rehabilitation Brain Injury Medicine

NPI
1972742161
CMS profile
134822
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$69,352.59

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan, Inc. $44,783.20 45
Ipsen Biopharmaceuticals, Inc $9,455.00 4
Ipsen Biopharm Limited $4,380.00 1
Ipsen Innovation $3,861.30 1
Merz Pharmaceuticals, LLC $3,412.26 9
PIRAMAL CRITICAL CARE $2,827.44 3
AbbVie Inc. $525.00 1
Penumbra, Inc. $108.39 1

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MONICA VERDUZCO-GUTIERREZ

NPI 1972742161 · CMS profile ID 134822

Allopathic & Osteopathic Physicians / Physical Medicine & Rehabilitation / Brain Injury Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972742161?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MONICA VERDUZCO-GUTIERREZ, NPI 1972742161, CMS profile ID 134822. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972742161?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MONICA VERDUZCO-GUTIERREZ, NPI 1972742161, CMS profile ID 134822. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972742161?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MONICA VERDUZCO-GUTIERREZ, NPI 1972742161, CMS profile ID 134822, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972742161?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $69,352.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merz Pharmaceuticals, LLC $44.7605/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845434705 CMS
Allergan, Inc. $11.7704/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974721 CMS
Merz Pharmaceuticals, LLC $18.6703/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845434703 CMS
Merz Pharmaceuticals, LLC $35.3403/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845434699 CMS
Merz Pharmaceuticals, LLC $85.8203/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845434701 CMS
Allergan, Inc. $12.4202/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974719 CMS
Allergan, Inc. $300.0002/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974717 CMS
Ipsen Biopharm Limited $4,380.0002/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763299306 CMS
Allergan, Inc. $8.7702/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974715 CMS
Allergan, Inc. $3,150.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974713 CMS
Allergan, Inc. $5.4701/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974711 CMS
Allergan, Inc. $2,400.0001/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974703 CMS
Allergan, Inc. $2,100.0001/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974705 CMS
Allergan, Inc. $750.0001/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974707 CMS
Allergan, Inc. $300.0001/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792974709 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,350.59 125
PY2020 $21,772.78 52
PY2021 $69,352.59 65
PY2022 $129,588.62 103
PY2023 $227,689.16 164
PY2024 $227,555.39 159
PY2025 $202,507.43 137

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $600.00 1
PY2025 Principal investigator $95,046.22 44
PY2024 Recipient $3,600.00 1
PY2024 Principal investigator $237,145.10 105
PY2023 Principal investigator $198,119.25 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Pharma SAS $4,425.00 08/29/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306271
Principal investigator 1 Ipsen Pharma SAS $900.00 08/29/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306297
Principal investigator 1 Ipsen Pharma SAS $500.00 08/29/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306299
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306263
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306265
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306273
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306277
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306287
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306289
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306305
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306307
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306313
Principal investigator 1 Ipsen Pharma SAS $450.00 08/28/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306319
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306253
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306255
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306257
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306259
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306261
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306267
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306269
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306275
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306279
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306281
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306283
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306285
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306291
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306293
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306295
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306301
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306303
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306309
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306311
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306315
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306317
Principal investigator 1 Ipsen Pharma SAS $3,140.80 08/08/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306321
Principal investigator 1 Ipsen Pharma SAS $174.42 07/11/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306251
Principal investigator 1 Ipsen Pharma SAS $2,566.85 06/23/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306249
Principal investigator 1 Ipsen Pharma SAS $2,566.85 05/19/2025 Non-covered Recipient Entity
University Texas Hlth Services
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307083
Principal investigator 1 Ipsen Pharma SAS $1,691.95 04/14/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306239
Principal investigator 1 Ipsen Pharma SAS $1,691.95 04/10/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306241
Principal investigator 1 Ipsen Pharma SAS $1,691.95 04/10/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306243
Principal investigator 1 Ipsen Pharma SAS $1,773.85 04/10/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306245
Principal investigator 1 Ipsen Pharma SAS $1,773.85 04/10/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184306247
Recipient ABBVIE INC. $600.00 02/06/2025 Covered Recipient Physician Ph 2 DRF Upper Limb Spasticity Study No dispute reported 06/30/2026 1202402259
Principal investigator 1 Ipsen Pharma SAS $1,691.95 01/29/2025 Non-covered Recipient Entity
The University Of Texas Health Science Center At San Antonio
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305821